Authors
Lawrence Y Agodoa, Lawrence Appel, George L Bakris, Gerald Beck, Jacques Bourgoignie, Josephine P Briggs, Jeanne Charleston, DeAnna Cheek, William Cleveland, Janice G Douglas, Margaret Douglas, Donna Dowie, Marquetta Faulkner, Avril Gabriel, Jennifer Gassman, Tom Greene, Yvette Hall, Lee Hebert, Leena Hiremath, Kenneth Jamerson, Carolyn J Johnson, Joel Kopple, John Kusek, James Lash, Janice Lea, Julia B Lewis, Michael Lipkowitz, Shaul Massry, John Middleton, Edgar R Miller III, Keith Norris, Daniel O'Connor, Akinlou Ojo, Robert A Phillips, Velvie Pogue, Mahboob Rahman, Otelio S Randall, Stephen Rostand, Gerald Schulman, Winifred Smith, Denyse Thornley-Brown, C Craig Tisher, Robert D Toto, Jackson T Wright Jr, Shichen Xu, African American Study of Kidney Disease and Hypertension (AASK) Study Group, African American Study of Kidney Disease and Hypertension (AASK) Study Group
Publication date
2001/6/6
Journal
Jama
Volume
285
Issue
21
Pages
2719-2728
Publisher
American Medical Association
Description
ContextIncidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.ObjectiveTo compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a β-blocker (metoprolol) on hypertensive renal disease progression.Design, Setting, and ParticipantsInterim analysis of a randomized, double-blind, 3 × 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m2) enrolled between February 1995 and September 1998. This report compares the ramipril and amlodipine groups following discontinuation of the amlodipine intervention in September 2000.InterventionsParticipants were …
Total citations
Scholar articles
LY Agodoa, L Appel, GL Bakris, G Beck, J Bourgoignie… - Jama, 2001